The new front-line in hepatitis B/D research: Identification and blocking of a functional receptor

Hepatology

Volumn 58, Issue 1, 2013, Pages 9-12

  Warner, Nadia ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DELTA AGENT HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIFE CYCLE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR BLOCKING; SEROCONVERSION; TREATMENT DURATION;

ANIMALS; FEMALE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LIVER; RECEPTORS, VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84879600641     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26292     Document Type: Article

References (20)

1. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
2. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121-1131.
3. Sierra-Aragon S, Walter H. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Intervirology 2012; 55: 84-97.
4. Nikolopoulos G, Bonovas S, Tsantes A, et al. HIV/AIDS: recent advances in antiretroviral agents. Mini Rev Med Chem 2009; 9: 900-910.
5. Taiwo B, Murphy RL, Katlama C. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Drugs 2010; 70: 1629-1642.
6. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. HEPATOLOGY 2013; 58: 31-42.
7. Schieck A, Schulze A, Gähler C, Müller T, Haberkorn U, Alexandrov A, et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. HEPATOLOGY 2013; 58: 43-53.
8. Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005; 129: 234-245.
9. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622.
10. Engelke M, Mills K, Seitz S, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. HEPATOLOGY 2006; 43: 750-760.
11. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
12. Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? HEPATOLOGY 2005; 42: 1453-1455.
13. Locarnini S, Civitico G, Newbold JE. Hepatitis B: New approaches for antiviral chemistry. Antiviral Chemistry & Chemotherapy 1996; 7: 53-64.
14. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005; 102: 1139-1144.
15. Zollner G, Wagner M, Fickert P, et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005; 25: 367-379.
16. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 2012; 1: e00049.
17. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007; 13: 22-38.
18. Suchanek M, Radzikowska A, Thiele C. Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells. Nat Methods 2005; 2: 261-267.
19. Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 1994; 93: 1326-1331.
20. Mareninova O, Shin JM, Vagin O, et al. Topography of the membrane domain of the liver Na+-dependent bile acid transporter. Biochemistry 2005; 44: 13702-13712.